Markets closed

Eli Lilly and Company

LLY · NYSE

Analyst Consensus

Buy

23 analysts

$1,138

Current

—

Low

$1,381

Average

—

High

Average target implies +21.28% versus the current price.

Analyst Ratings Synthesis

Consensus is Buy from 23 analysts, with a mean price target of $1,380.50; the supplied consensus reports no low or high target, so the target spread cannot be measured. Other supplied aggregators show materially different coverage counts and averages, including 19 analysts with a Strong Buy consensus and a $1,217.79 target at StockAnalysis, 30 analysts with a Buy rating and a $1,315.56 target, and TipRanks’ $1,382.05 average. No named firm is identified as the most or least bullish, and no explicit rating or target revisions are documented during the past week. The substantive disagreement is the balance between obesity-driven growth and valuation, pricing, competition, and execution risk.

Rating Actions

No individual rating actions have been captured for LLYyet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

ARGUS RESEARCH

B OF A GLBL RES

BARCLAYS CAPITA

BERENBERG BANK

BMO CAPITAL MKT

CANTOR FITZGERA

CITIGROUP

CO FORECST

DAIWA AMERICA

DEUTSCHE BK SEC

EDWARD JONES

GOLDMAN SACHS

GUGGENHEIM SEC.

HSBC GLOBAL RES

JEFFERIES & CO.

JP MORGAN SECUR

LEERINK PARTNRS

MORGAN STANLEY

TD COWEN

TRUIST SECURITI

UBS

WELLS FARGO SEC

ZACKS RESEARCH

Symbol: LLY
Type: Stock
Sector: Health Care
Industry: Pharmaceutical Preparations
Exchange: NYSE

Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people.

Key Issues

Bullish view

Continued demand for Lilly’s two-drug obesity treatment and fresh obesity-drug data could support further revenue growth and justify the company’s valuation.

Bearish view

A valuation near $1 trillion leaves limited room for disappointment, while competition, pricing pressure, and the need to sustain volume could undermine the obesity thesis.

Analyst Consensus

See all

Buy

23 analysts

$1,138

Current

—

Low

$1,381

Average

—

High

Average target implies +21.28% versus the current price.

Earnings History

BeatMissNo estimate

Eli Lilly and Company

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers